Drug Trial Radar · NCT02651662
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jan 11, 2016
Primary completion
Apr 29, 2026
Study completion Apr 29, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab. This study is also looking at several other research questions, including: * What side effects may happen from taking the study drugs * How effective the study drugs are against the disease * How much study drug is in the blood at different times * Whether the body makes substances or protein called antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)
Conditions
- Relapsed/Refractory Aggressive B-Cell Lymphoma
Interventions
cemiplimabDrug
Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
odronextamabDrug
Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) of cemiplimab in combination with odronextamabTime frame: Up to 28 days
- Incidence of treatment emergent adverse events (TEAEs) of cemiplimab in combination with odronextamabTime frame: Up to 18 months
- Severity of TEAEs of cemiplimab in combination with odronextamabTime frame: Up to 18 months
- Incidence of adverse events of special interest (AESIs) of cemiplimab in combination with odronextamabTime frame: Up to 18 months
- Severity of AESIs of cemiplimab in combination with odronextamabTime frame: Up to 18 months
Locations
30 sites in 6 countries. Site status is shown where the registry gives one.
Johns Hopkins University
Baltimore, Maryland
Dana Farber/Harvard Cancer Center - PO box 849168
Boston, Massachusetts
Harvard Medical School - Beth Israel Deaconess Medical Center
Boston, Massachusetts
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III
Salzburg, Austria
Medical University Vienna
Vienna, Austria
University Hospital Frankfurt
Frankfurt am Main, Germany
Universitatsklinikum Jena
Jena, Germany
Universitatsklinikum Schleswig-Holstein, Campus Kiel
Kiel, Germany
Soroka
Beersheba, Israel
Hadassah Medical Center
Jerusalem, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Pratia Onkologia Katowice
Katowice, Poland
Copernicus Memorial Hospital
Lodz, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
Warsaw, Poland
Pratia MCM Krakow
Krakow, Malopolska, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Pomeranian Voivodeship, Poland
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Institut Catala dOncologia (ICO Hospitalet)
Barcelona, Spain
MD Anderson Cancer Center- Madrid
Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Clinico Universitario de Salamanca
Salamanca, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda, Madrid, Spain
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.